Skip to main content

Market Access for Medical Technologies in France

A brief overview of key market access pathways and challenges for medical devices, in-vitro diagnostic tests in France

sdfg

Key Topics

There is only one key theme describing market access for medical technologies in France:

  • Reimbursement: payment mechanism via DRG system, add-on reimbursement via LPPR List

There is no separate funding (approval by the payer) or health technology assessment challenges in France. HTA is integrated into reimbursement decision-making. 

France has a number of innovative payment schemes for medical technologies. 

dx

Reimbursement

Reimbursements for hospital procedures are made solely via a DRG system, which is called “Groupe Homogène de Maladies” (GHM). All hospitalizations, as well as day case procedures and ambulatory treatments, are reimbursed via DRG.

The DRG system has several components.

Diagnosis-related groups:

  • Each DRG in the French system has four severity levels, from level 1 (lowest severity) to level 4 (highest severity). The severity level is determined by the length of the stay, the presence of complications, the type of procedure performed, etc. There are also DRGs for a short stay, which can cover hospital day care or one-day hospitalizations
  • DRGs are determined by the combination of a procedure code (CCAM) and a diagnosis code (ICD-10). 
  • DRG tariffs differ between public, private not-for-profit, and private for-profit hospitals. Private for-profit hospitals have lower tariffs, but physicians practicing there receive a fee for every procedure performed, based on fees determined for each CCAM code.

Add-on reimbursement (LPPR list):

  • This is an add-on reimbursement category for selected implantable (Title III) or invasive non-implantable (Title V) devices.
  • The LPPR list is primarily managed by the French National Authority for Health (Haute Autorité de Santé, HAS). The industry can either make a brand-specific or a generic application to request the inclusion of its products into the LPPR catalog. Technologies for which evidence is considered sufficient are listed, and their price is determined at the national level. The price is based on the level of added value the device provides compared to the current standards of care in France.
  • Clinical assessment is performed by National Committee for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS), and price negotiation is performed by Economic Committee on Healthcare Products (CEPS).
  • The DRG system is approved annually. The DRG system is administered by the Technical Agency for Hospital Information (Agence technique de l'information sur l'hospitalisation, ATIH). Neither the industry nor the providers have a direct impact on the development of the DRG system. However, some lobbying groups can have an impact.
111

Specifics for IVD Tests

In-vitro diagnostic tests are reimbursed using a fee-for-service mechanism via NABM Nomenclature.

Innovative tests are funded by the Ministry of Labor, Health, and Solidarity  via RIHN and Supplementary List mechanisms. 

However, in 2023, the reform of this innovation framework was announced, and in spring 2024 the authorities announced the details of the reform. In the summer of 2024, the Ministry of Health released the 2024 List of IVD tests outside the Nomenclature (LAHN), which is the merged 2023 RIHN List and the Supplementary List, with a total of 616 tests. Currently, the French High Authority for Health (HAS) is evaluating expensive tests listed in the LAHN with the purpose of deciding whether these tests will be granted permanent reimbursement or will be excluded from coverage within the statutory health insurance. Cleaning the current AHN List will allow for the financing of truly innovative tests patients need. 

Finally, the authorities launched a new process for the registration of new innovative tests in the new List under the RIHN 2.0 framework.

MTRC has experience with more than 321 projects in France

News and Insights

Order updating the regulation of point-of-care tests released in France

On February 7, 2026, the Ministry of Health, Family, Autonomy and People with Disability released an update of the 2014 regulations on conditions of performing IVD tests outside the medical biology laboratory. The new regulation expands the list of locations eligible for point-of-care testing (POCT) and provides an explicit list of tests that can be performed as POCT, and links them to eligible locations. It also introduces a quality assurance framework, accreditation requirements, and mandates that comprehensive conventions be concluded between the remote sites providing POCT and the responsible laboratories.

Application open for the assessment of procedures and IVD tests by HAS in France

In early February 2026, the French National Authority for Health (HAS) opened the call for applications for the evaluation of medical procedures and in-vitro diagnostic (IVD) tests to be included in its 2027 working program. The deadline for submission is May 4, 2026.

January 2026 recommendations about add-on reimbursement for medical devices in France

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the January 2026 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). A favourable opinion was issued on the add-on reimbursement for one new device, as well as on the extension of indications for two devices for transcatheter aortic valve implantation.

Get in Touch

Contact us to discuss your needs and learn about our services